From CGRP to PACAP, VIP, and Beyond: Unraveling the Next Chapters in Migraine Treatment
Cells · 17.11.2023 · 12 (22) · 2649
DOI: 10.3390/cells12222649 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 17.11.2023. Verfasst von Masaru Tanaka und 5 weiteren Autor:innen. Beteiligte Einrichtung: HUN-REN-SZTE Neuroscience Research Group, Hungarian Research Network, University of Szeged (HUN-REN-SZTE), Danube Neuroscience Research Laboratory, T…. Hauptthemen laut MEDLINE: Gastrointestinal Hormones, Migraine Disorders. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 244 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: OTKA, TUDFO, HUN-REN-SZTE Neuroscience Research Group, Hungarian Research Network, University of Sze-ged (HUN-REN-SZTE).
Abstract (Originalsprache)
Migraine is a neurovascular disorder that can be debilitating for individuals and society. Current research focuses on finding effective analgesics and management strategies for migraines by targeting specific receptors and neuropeptides. Nonetheless, newly approved calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) have a 50% responder rate ranging from 27 to 71.0%, whereas CGRP receptor inhibitors have a 50% responder rate ranging from 56 to 71%. To address the need for novel therapeutic targets, researchers are exploring the potential of another secretin family peptide, pituitary adenylate cyclase-activating polypeptide (PACAP), as a ground-breaking treatment avenue for migraine. Preclinical models have revealed how PACAP affects the trigeminal system, which is implicated in headache disorders. Clinical studies have demonstrated the significance of PACAP in migraine pathophysiology; however, a few clinical trials remain inconclusive: the pituitary adenylate cyclase-activating peptide 1 receptor mAb, AMG 301 showed no benefit for migraine prevention, while the PACAP ligand mAb, Lu AG09222 significantly reduced the number of monthly migraine days over placebo in a phase 2 clinical trial. Meanwhile, another secretin family peptide vasoactive intestinal peptide (VIP) is gaining interest as a potential new target. In light of recent advances in PACAP research, we emphasize the potential of PACAP as a promising target for migraine treatment, highlighting the significance of exploring PACAP as a member of the antimigraine armamentarium, especially for patients who do not respond to or contraindicated to anti-CGRP therapies. By updating our knowledge of PACAP and its unique contribution to migraine pathophysiology, we can pave the way for reinforcing PACAP and other secretin peptides, including VIP, as a novel treatment option for migraines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- HUN-REN-SZTE Neuroscience Research Group, Hungarian Research Network, University of Szeged (HUN-REN-SZTE), Danube Neuroscience Research Laboratory, Tisza Lajos krt. 113, H-6725 Szeged, Hungary.
- Department of Neurology, Albert Szent-Györgyi Medical School, University of Szeged, Semmelweis u. 6, H-6725 Szeged, Hungary.
- Doctoral School of Clinical Medicine, University of Szeged, Korányi fasor 6, H-6720 Szeged, Hungary.
- Faculty of Health Sciences and Social Studies, University of Szeged, Temesvári krt. 31, H-6726 Szeged, Hungary.
- Preventive Health Sciences Research Group, Incubation Competence Centre of the Centre of Excellence for Interdisciplinary Research, Development and Innovation of the University of Szeged, H-6720 Szeged, Hungary.
ORCID-Profile: Masaru Tanaka, Ágnes Szabó, Tamás Körtési, Délia Szok, János Tajti, László Vécsei
Förderung
- OTKA
- TUDFO
- HUN-REN-SZTE Neuroscience Research Group, Hungarian Research Network, University of Sze-ged (HUN-REN-SZTE)
- HUN-REN Hungarian Research Network
Zitieren
APA
Tanaka, M., Szabó, Á., Körtési, T., Szok, D., Tajti, J., & Vécsei, L. (2023). From CGRP to PACAP, VIP, and Beyond: Unraveling the Next Chapters in Migraine Treatment. Cells, 12(22), 2649. https://doi.org/10.3390/cells12222649
Vancouver
Tanaka M, Szabó Á, Körtési T, Szok D, Tajti J, Vécsei L. From CGRP to PACAP, VIP, and Beyond: Unraveling the Next Chapters in Migraine Treatment. Cells. 2023;12(22):2649. doi:10.3390/cells12222649
BibTeX
@article{Tanaka2023,
author = {Tanaka, Masaru and Szabó, Ágnes and Körtési, Tamás and Szok, Délia and Tajti, János and Vécsei, László},
title = {From CGRP to PACAP, VIP, and Beyond: Unraveling the Next Chapters in Migraine Treatment},
journal = {Cells},
year = {2023},
volume = {12},
number = {22},
pages = {2649},
doi = {10.3390/cells12222649}
}
EUVIMED